Drug Trial Radar · NCT05469360
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
38
Actual
Start
Feb 23, 2023
Primary completion
Jul 30, 2026
Study completion Sep 24, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
Conditions
- Alzheimer Disease
- Mild Cognitive Impairment
Interventions
NIO752Drug
A single intrathecal (cerebrospinal) injection of NIO752 of Dose A
NIO752Drug
A single intrathecal (cerebrospinal) injection of NIO752 at dose B
Matching placeboDrug
A single intrathecal injection of matching placebo
NIO752Drug
Multiple intrathecal injections of NIO752 of Dose A
NIO752Drug
Two intrathecal injections of NIO752 at dose C
NIO752Drug
Single intrathecal injection of NIO752 at dose C
Matching placeboDrug
Two intrathecal injections of matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in cerebrospinal total tau from baseline to Day 85Time frame: Baseline, Day 85
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Kuopio, Finland
Novartis Investigative Site
Turku, Finland
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Malmö, Sweden
Novartis Investigative Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.